

Pulling together: Canadian perspectives on incentivizing antimicrobial availability

A Council of Canadian Academies' Expert Panel Assessment



Andrew M. Morris M.D, Expert Panel Chair



The Public Health Agency of Canada asked the CCA to convene a panel of experts to answer the following question:

What economic pull incentives have the greatest potential for success in encouraging the market entry and sustained market availability of high-value antimicrobials for use in humans in Canada?



Push incentives
encourage R&D



Pull incentives
encourage
commercialization

THE CANADIAN CONTEXT



Significant AMR Impact

- In 2018, 14,000+ AMR-associated deaths & \$1.4 billion in healthcare costs

Limited Access to Novel Antimicrobials


- Only 3 of the 18 recently developed antimicrobials are accessible in Canada

Multi-actor Healthcare Systems

- Federal oversight of drug safety
- Healthcare delivery is a provincial mandate
- Many payers: 10 provinces and 3 territories with separate health insurance plans, some federal plans, some private insurance

SUBSCRIPTION PULL INCENTIVE (SPI)

A well-designed SPI holds the most promise for bringing existing novel antimicrobials to market and motivating the development and commercialization of new ones



Stringent eligibility criteria: qualifying drugs address unmet public health needs and exhibit novelty



Access and stewardship: provisions built into contracts




Paying for value: higher payment levels for drugs providing greater value



Re-evaluate drug value over time: eligibility and payment levels revisited as new evidence emerges

IMPLEMENTING AN SPI IN CANADA



Collaboration among all actors in Canadian healthcare systems



Committee of experts assesses a drug's value (building on learnings from UK subscription incentive)



Time restrictions on eligibility to incentivize new drugs coming to the Canadian market in a timely manner



Fixed unit sale price to support appropriate use



Federal top up to provincial and territorial sales revenues



THE COST OF INCENTIVIZING ANTIMICROBIAL AVAILABILITY



Panel assessed estimates of the costs of incentivizing development

Landed on best estimate of US\$ 3.1 billion per drug over 10 years

Canada's fair share
C\$ 14.5 - 18 M
per year per drug
over 10 years



Growing consensus that the value of novel antimicrobials to the public exceeds the costs of incentivizing their development

FIND OUT MORE



www.cca-reports.ca



[@cca_reports](#)



info@cca-reports.ca